Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%
Ph phase_2
2
40%

Phase Distribution

1

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 22 (40.0%)
Phase 32 (40.0%)

Trials by Status

not_yet_recruiting240%
recruiting360%

Recent Activity

3 active trials
Showing 5 of 5
recruitingphase_3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152
not_yet_recruitingphase_2

Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.

NCT07808567
recruitingphase_1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT06835569
not_yet_recruitingphase_3

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

NCT07336953
recruitingphase_2

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

NCT05268692

Clinical Trials (5)

Showing 5 of 5 trials
NCT07562152Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting
NCT07808567Phase 2

Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.

Not Yet Recruiting
NCT06835569Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Recruiting
NCT07336953Phase 3

A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

Not Yet Recruiting
NCT05268692Phase 2

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5